# Pancreatic Cancer Tumor Markers 

## Featured Products

Pancreatic cancer is the third leading cause of cancer-related death in the United States. With a predicted five-year relative survival rate of $9 \%$, pancreatic cancer continues to be clinically challenging due to its resistance to even the most aggressive combinations of surgery, chemotherapy, and radiotherapy. Because of indistinct symptoms and the absence of reliable diagnostic biomarkers, diagnoses are usually delayed and thus made when the disease is already advanced (which decreases five-year survival to less than $3 \%$ ). Nevertheless, extensive research has highlighted the importance of several biomarkers and reagents that can significantly improve early detection.


CA19-9 antibody [GT933] (GTX635389) (1)


Thrombospondin 2 antibody (GTX134554) 10


CEA antibody [Col-1] (GTX17254) ©


RAS (G12D Mutant) antibody [HL10] (GTX635362) (1)


Pancreatic Polypeptide antibody [GT6512] (GTX628832)


Glypican 1 antibody [N3C3] (GTX104557) © (19/金

alpha amylase 2A (pancreatic) antibody [6D4] (GTX84887) ©

Representative Product Lists
IP/MS Analysis
Orthogonal Validation


